Navigation Links
New Handheld Base Unit for CoaguChek XS Plus System Enables Connectivity to RALS-Plus Data Management Solution for PT/INR Testing at the Point of Care
Date:11/11/2008

ped the RALS system. "RALS-Plus is designed to do both."

The most significant benefits of connectivity with RALS-Plus relate to enhanced patient safety and quality control, according to Robert Hach, Point of Care Coordinator at Cleveland's MetroHealth System, which has been using RALS-Plus to manage its POC blood glucose testing program for five years and served as a test site for the CoaguChek XS Plus connectivity module. "During the beta test, the connectivity to RALS-Plus allowed us to control the PT/INR meters remotely, so we could manage operator certification and protocol compliance from one location," he says. "That took away any worries about an unauthorized person using the meter, and helped ensure the safety of our patients."

RALS-Plus helps hospitals address quality initiatives by giving them centralized control of point-of-care testing devices, including Roche's ACCU- CHEK(R) Inform system for blood glucose, according to Keith Snyder, Director of IT Marketing at Roche. "Now facilities that use the CoaguChek XS Plus System can extend the benefits of centralized data management to point-of-care testing in their warfarin clinics as well," he said.

The CoaguChek XS Plus System can store up to 500 patient and/or liquid quality control results that can be searched by patient ID, date, and time. It uses two-level, built-in quality controls to help ensure the accuracy of PT/INR test results, but also offers optional liquid quality controls for facilities with policies requiring the use of external quality control measures.

About Anticoagulation Monitoring

Patients with atrial fibrillation, a mechanical heart valve and other conditions often require protection against thrombosis, or blood clots. They are typically put on lifelong oral anticoagulation therapy with Coumadin (warfarin) to thin their blood. Each patient reacts differently to anticoagulant medication, so it is imperative to monitor the therapeutic effects to keep pot
'/>"/>

SOURCE Roche Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
2. Aribex Unveils New Handheld Intraoral X-ray System - NOMAD Pro
3. Handheld DNA detector
4. Different method of evaluating the urinary tract system reduces radiation dose
5. Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education
6. Exempla Healthcare Contracts For Talismans Quality Donor System
7. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
8. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
9. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
10. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
11. Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5NMB 26apos 3Bs New Series of Standard Hybrid Stepper Motors Now Available 54875 1NMB 26apos 3Bs New Series of Standard Hybrid Stepper Motors Now Available 54875 2National Senior Citizens Day Celebrated August 21 Amid Health Care Reform Debate 54871 1National Senior Citizens Day Celebrated August 21 Amid Health Care Reform Debate 54871 2National Senior Citizens Day Celebrated August 21 Amid Health Care Reform Debate 54871 3Aton Pharma Launches Expanded Distribution and Marketing for Preservative Free TIMOPTIC 28R 29 in OCUDOSE 28R 29 54867 1Aton Pharma Launches Expanded Distribution and Marketing for Preservative Free TIMOPTIC 28R 29 in OCUDOSE 28R 29 54867 2Aton Pharma Launches Expanded Distribution and Marketing for Preservative Free TIMOPTIC 28R 29 in OCUDOSE 28R 29 54867 3Aton Pharma Launches Expanded Distribution and Marketing for Preservative Free TIMOPTIC 28R 29 in OCUDOSE 28R 29 54867 4